Just in time for the holidays, CancerKB 4.0 is now available to incorporate into your cancer analysis workflows! We have termed this release “The Hematological release” as we boast of complete coverage of the NCCN Guidelines recommended therapies and FDA-approved therapies for all hematological cancers in our Drug Sensitivity Interpretations. We have also reviewed and synthesized the consensus from the NCCN Guidelines, World Health Organization Blue Books, and International Consensus Classification publications to write prognosis and diagnostic interpretations for the most prevalent blood cancers and their subtypes, including acute myeloid leukemia, myeloproliferative neoplasms, myelodysplastic syndromes, chronic lymphocytic leukemia, and chronic myelogenous leukemia.
The focus on capturing and harmonizing the diagnostic and prognostic information into report-ready interpretations for these tumor types sets CancerKB apart from comparable databases. Diagnostic and prognostic information is not easily extracted from resources in the cancer space, and the most trusted resources, such as the NCCN and WHO guidelines, can have somewhat conflicting information for classifying, diagnosis, and treating patients. We believe this is an important release because CancerKB now offers a solution to provide this information for patients, and the best part is you do not have to spend hours and effort hunting down and summarizing this information into a written interpretation.
We started generating prognosis and diagnosis interpretations for the most prominent blood cancers because these are the most complex cancers to diagnose and provide accurate prognoses for. The curation team plans to continue working towards building out the diagnostic and prognostic interpretations available within CancerKB to cover all hematological cancers and solid tumors.
To support the additional drug sensitivity, diagnostic, and prognostic clinical interpretations for the hematological cancers, there are 150+ new biomarker summaries, nearly 1000 fully curated genes with tumor-specific outcomes and frequency interpretations, and close to 65,000 clinical trials to reference for patient therapeutic options and evidence. Figure 1 provides a nice summary of what CancerKB 4.0 has to offer.
If you have questions about how to incorporate Golden Helix CancerKB into your cancer workflows to take advantage of everything that CancerKB has to offer, please reach out to us at [email protected]. In addition, stay tuned for an upcoming webcast that will discuss somatic variant analysis and workflow automation, including a demonstration of CancerKB 4.0 in action!